Oxygen therapy in the breathless patient

Beasley and colleagues argue persuasively that oxygen delivery to hypoxaemic patients should be optimised to provide adequate oxygen delivery while reducing the adverse effects of hyperoxaemia and preventing delay in identifying a patient with deteriorating gas exchange.1 However, their consistent use of the term high-flow oxygen instead of high-concentration oxygen perpetuates another widespread misunderstanding regarding oxygen therapy—that oxygen flow to the patient has a consistent and predictable relationship to the fractional inspired oxygen concentration (FiO₂) delivered to the alveoli. This incorrect assumption threatens to undermine the wisdom and potential benefits of their insightful editorial.

When oxygen is delivered by nasal cannula, Hudson mask or reservoir bag mask, the inspiratory flow generated by the patient will generally exceed the oxygen flow delivered.2 Room air is entrained by the patient and thus the inspired oxygen is diluted. During the expiratory phase, oxygen flow continues and has a variable and unpredictable effect of flushing exhaled gases from the device and filling the upper airways with high concentration oxygen. Therefore, as respiratory rate, inspiratory flow and tidal volume change, so does the FiO₂ arriving in the patient’s alveoli. These devices are referred to as “variable performance devices”. Venturi systems blend oxygen and gas at a fixed ratio and the total gas flow delivered to the patient usually exceeds inspiratory flow when FiO₂ is <40% (fig 1). These devices, along with gas blenders and mechanical ventilators, are “fixed performance”.

In the case example shown on page 841 of the editorial by Beasley et al,1 the theoretical patient is provided in part (a) with an FiO₂ of 0.3 (2–3 litres via nasal cannula) and subsequently (b) with an FiO₂ of 0.6 (8–10 litres via a Hudson mask). These numbers are erroneous since both employ a variable performance device.

B D Fox
Correspondence to: Dr B D Fox, Pulmonary Institute, Rabin Medical Center (Beilinson Campus), Petach Tiqwa 49100, Israel; benfox@post.tau.ac.il
Competing interests: None.

REFERENCES

Author’s reply

We thank Dr Fox for the important point he makes regarding the use of fixed performance devices to deliver a predetermined concentration of oxygen. However, we consider that his concerns are not central to the theme of the commentary. In our case example, oxygen was administered by nasal prongs and a Hudson mask to describe two different approaches to oxygen therapy commonly used in the management of pneumonia. As discussed in our commentary, we contend that, in this clinical situation, the crucial issue is the titration of oxygen therapy to relieve hypoxaemia without causing hyperoxia, with continuous monitoring of the response by measurement of the oxygen saturation.

R Beasley
Correspondence to: Professor R Beasley, Medical Research Institute of New Zealand, P O Box 10055, Wellington, New Zealand; richard.beasley@mrinz.ac.nz
Competing interests: None.

High effectiveness of short treatment with bupropion for smoking cessation in general care

Since the appearance of the seminal publication on sustained release bupropion versus placebo for smoking cessation exactly 10 years ago,1 bupropion has become a mainstay of nicotine addiction therapy.2 Some concerns relating to increased risk of seizures remain, in particular as exclusion of predisposed patients may be suboptimal in general practice.3 Furthermore, the cost of about €135 or US$180 for a pack of 100 pills required for a standard course of treatment of at least 7 weeks represents a substantial barrier to wider use.4 We present data suggesting that much shorter treatments with bupropion may be as effective as standard regimens.

In a cluster randomised trial in German general care investigating the effects of practitioner education and financial incentives for the physician or cessation drug costs reimbursement for his/her patients on smoking cessation, 577 heavy smokers (10+ cigarettes/day) aged 36–75 years and willing to participate were recruited regardless of their intentions to quit.5 At the 12 month follow-up, 76 participants (13%) reported having used bupropion (Zyban) during the 1 year study period. Consistent with expectations from clinical trials,6 cotinine confirmed point prevalence of abstinence after 1 year in subjects who had taken bupropion was 26% (20/76). However, we observed that the majority of treated patients reported intake durations clearly below the recommendations. In particular, 25 (33%) and 34 (45%) reported having taken bupropion for only 1–2 and 3–4 weeks, respectively. Intriguingly, in adjusted analyses, strong and significant associations of bupropion with cessation were evident only in the two categories representing treatment clearly shorter than current standards (table 1). This was preserved when using a stricter outcome (ie, 6 months of continuous abstinence).

REFERENCES

Figure 1 Composition of total gas flows through a typical Venturi valve.
Oxygen therapy in the breathless patient

B D Fox

Thorax 2008 63: 476

Updated information and services can be found at:
http://thorax.bmj.com/content/63/5/476.1

These include:

References
This article cites 2 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/63/5/476.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/